Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 08:00 am ET
Good day, and welcome to the BrainStorm Cell Therapeutics First Quarter 2020 Conference Call. At this time, all participants are in listen-only mode. As a reminder, this call is recorded. And I would now like to introduce your host for today's conference, Mr. Sean Leous from ICR Westwicke. Mr. Leous, you may begin.
Thank you for joining the BrainStorm Cell Therapeutics call. Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts and projections regarding BrainStorm Cell Therapeutics, NASDAQ: BCLI, and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of our NurOwn technology platform, our clinical trials of NurOwn and related clinical development programs, and our ability to develop strategic collaborations and partnerships to support our business planning efforts.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected here on today's call. We undertake no obligation to publicly update any forward-looking statements.
Joining me on the call today will be Chaim Lebovits, President and CEO of BrainStorm; Dr. Ralph Kern, President and Chief Medical Officer; David Setboun, Chief Operating Officer, Preetam Shah, Chief Financial Officer. They will be available to answer your questions during the Q&A session.
Thank you, Sean. Good morning and good afternoon to everyone on the first quarter 2020 earnings call. I would like to begin by thanking everyone for participating in today's call and for all those that sent the questions prior to our call. We will address many of your pre-submitted questions in the opening remarks, and we look forward to addressing any additional questions or comments you may have during the Q&A session.
Although the global markets and the coronavirus pandemic has impacted all of us, the first quarter of 2020 has been productive for Brainstorm, as we continued to execute on our goal of bringing much needed treatment to those suffering from neurodegenerative disease.
On behalf of the entire Brainstorm management team, I would like to express my sincere appreciation for the ongoing dedication and support we have received from patients, their families, caregivers and all of those who are helping us advance the Phase III ALS clinical trial. I also want to thank our team at Brainstorm who fully devote themselves to advance best-in-class and potentially life-altering therapies. And finally, I would like to thank our shareholders for their continued ongoing support on our collective journey to a potential FDA approval of NurOwn in ALS.
We are happy to share with you that our fully enrolled Phase III ALS clinical trial remains on track with a Q4 2020 top line data readout. Due to the pandemic, our partner healthcare